secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2026-06-04T20:05:17+00:00
Accession:  0001193125-26-257368
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology stockholders approve 6.5M share increase for equity plan and 2.5M for ESPP at annual meeting
--------------------------------------------------------------------------------

- Stockholders approved amendment to 2014 Equity Incentive Plan, increasing authorized shares by 6.5 million.
- Stockholders approved amendment to 2015 ESPP, increasing authorized shares by 2.5 million.
- Elected three Class III directors: Diane Parks, Mary T. Szela, and Michael J. Vasconcelles, M.D. to terms expiring 2029.
- Ratified Ernst & Young as independent auditor for FY2026; 69.4M for, 140.8K against.
- Advisory Say-on-Pay approved (48.8M for, 1.1M against); board set future votes every year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312526257368/0001193125-26-257368-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312526257368/kura-20260604.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-257368

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer